Insurers and drug-industry middlemen are cashing in on the weight-loss drug frenzy

• Demand for drugs like Ozempic could boost health insurers' bottom lines, according to BofA.
• Insurers and the drug-industry middlemen they own stand to earn more as healthcare spending increases.
• Insurers' membership could also swell if the drugs help people live longer. 

For US health insurers, explosive demand for new weight-loss drugs likely means bigger profits.